FDA Approved: FLUTICASONE PROPIONATE HFA — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for Fluticasone Propionate HFA submitted by Prasco Laboratories, leading to labeling changes under NDA 021433.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone Propionate HFA (Fluticasone Propionate)

Snippet

SUPPL AP for FLUTICASONE PROPIONATE HFA (FLUTICASONE PROPIONATE)